Table 3.
Serological findings in patients with DIHA
| Drug | n | DAT* |
Eluate |
IAT pos | Concomitant aab | ddab** |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG | C3d | pos | neg | n.t. | drug | ex vivo | drug / ex vivo | ||||
| Diclofenac | 23 | 19 | 17 | 17 | 4 | 2 | 16 | 18 | 1 | 10 | 12 |
| Piperacillin | 13 | 13 | 11 | 4 | 9 | − | 5 | 2 | 3 | 2 | 8 |
| Cephalosporins | |||||||||||
| Ceftriaxon | 12 | 10 | 12 | 1 | 9 | 2 | 3 | 2 | − | 2 | 11 |
| Cefotaxim | 2 | − | 2 | − | 2 | − | 1 | − | − | 1 | 1 |
| Platinum-based agents | |||||||||||
| Oxaliplatin | 10 | 10 | 8 | 5 | 4 | 1 | 0 | − | n.t. | n.t. | 10 |
| Carboplatin | 1 | 1 | 1 | 1 | − | − | 1 | 1 | n.t. | n.t. | 1 |
| Rifampicin | 4 | 4 | 4 | 1 | 3 | − | 4 | 2 | n.t. | n.t. (2/4) | 4 |
| Radiocontrast media | |||||||||||
| Iomeprol | 1 | − | 1 | 1 | − | − | 1 | 1 | n.t. | n.t. | 1 |
| Iohexol | 1 | − | 1 | 1 | − | − | 1 | − | n.t. | n.t. | 1 |
| Etoricoxib | 1 | 1 | 1 | − | 1 | − | 1 | − | − | − | 1 |
| 5-FU | 1 | 1 | 1 | − | 1 | − | 1 | 1 | − | 1 | − |
| Ibuprofen | 1 | − | 1 | − | 1 | − | 0 | − | − | − | 1 |
| Clindamycin | 1 | 1 | 1 | − | 1 | − | 1 | 1 | − | − | 1 |
| Vancomycin | 1 | − | 1 | − | 1 | − | 1 | n.t. | n.t. | 1 | |
| Cotrimoxazol | 1 | 1 | 1 | − | 1 | − | 0 | − | − | 1 | |
| Total | 73 | 31 | 37 | 5 | 36 | 28 | 17 | ||||
n.t. = Not tested; drug / ex vivo: drug, and if tested, ex vivo positive.
*
DAT: 1 patient had IgA only positive DAT; 1 patient had negative DAT.
**
Drug: drug positive only; ex vivo: ex vivo positive only; drug / ex vivo: drug, and if tested, ex vivo positive.